Instituto de Investigación Sanitaria Gregorio Marañón-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2024

  1. N-acetylcysteine during critical neurodevelopmental periods prevents behavioral and neurochemical deficits in the Poly I:C rat model of schizophrenia

    Translational Psychiatry, Vol. 14, Núm. 1

  2. THC improves behavioural schizophrenia-like deficits that CBD fails to overcome: a comprehensive multilevel approach using the Poly I:C maternal immune activation

    Psychiatry Research, Vol. 331

2023

  1. Neuroimaging Revealed Long-Lasting Glucose Metabolism Changes to Morphine Withdrawal in Rats Pretreated with the Cannabinoid Agonist CP-55,940 during Periadolescence

    European Neuropsychopharmacology, Vol. 69, pp. 60-76

2022

  1. Sphk2 deletion is involved in structural abnormalities and Th17 response but does not aggravate colon inflammation induced by sub-chronic stress

    Scientific Reports, Vol. 12, Núm. 1

  2. The effects of mango leaf extract during adolescence and adulthood in a rat model of schizophrenia

    Frontiers in Pharmacology, Vol. 13

2021

  1. A Characterization of the Effects of Minocycline Treatment during Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders

    International Journal of Neuropsychopharmacology, Vol. 24, Núm. 9, pp. 734-748

  2. Omega-3 fatty acids during adolescence prevent schizophrenia-related behavioural deficits: Neurophysiological evidences from the prenatal viral infection with PolyI:C

    European Neuropsychopharmacology, Vol. 46, pp. 14-27

2019

  1. Risperidone administered during adolescence induced metabolic, anatomical and inflammatory/oxidative changes in adult brain: A PET and MRI study in the maternal immune stimulation animal model

    European Neuropsychopharmacology, Vol. 29, Núm. 7, pp. 880-896

2018

  1. Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis

    International Journal of Neuropsychopharmacology, Vol. 21, Núm. 5, pp. 410-422